{"id":807698,"date":"2025-02-03T07:34:55","date_gmt":"2025-02-03T12:34:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/"},"modified":"2025-02-03T07:34:55","modified_gmt":"2025-02-03T12:34:55","slug":"briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/","title":{"rendered":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Lung metastasis (from metastatic breast cancer) resolved &#8211; after only 2 months (4 doses) of treatment with Bria-OTS\u2122 monotherapy<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>No toxicity related to the treatment; Patient remains on study<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Unprecedented result in first patient dosed supports Bria-OTS\u2122 personalized immunotherapy approach<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Ongoing Phase 1\/2a dose escalation study to evaluate Bria-OTS\u2122, BriaCell&#8217;s personalized off-the-shelf immunotherapy in metastatic breast cancer <\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Feb.  03, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient is the first metastatic breast cancer (MBC) patient treated with Bria-OTS\u2122.<\/p>\n<p align=\"justify\">Bria-OTS\u2122 is a personalized off-the-shelf immunotherapy, currently under investigation in a Phase 1\/2a dose escalation study (ClinicalTrials.gov identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CRfkAlRP3Lq1TM2yq6sGXF-Bpqe3QUBIoBWLrylh1VD3NXd--Fm_N0V73bh6lQjjB3pFZd1umm604fbh4BnAkGj-1s7wsdXh1cIIZTOoCKSpD6iIXeJA3TvSjmnyfsNiJrgxbFUlQTy5Mya7G6cbFA==\" rel=\"nofollow\" target=\"_blank\">NCT06471673<\/a>) in metastatic recurrent breast cancer. Bria-OTS\u2122 represents a personalized, next generation, advancement of BriaCell\u2019s lead candidate Bria-IMT\u2122 which is currently in a pivotal Phase 3 study for metastatic breast cancer.<\/p>\n<p align=\"justify\">\n        <strong>Figure 1: Treatment with Bria-OTS\u2122 monotherapy resulted in 100% resolution of tumor in the lung of the MBC patient following 4 injection cycles<\/strong><br \/>\n        <sup><br \/>\n          <strong>1<\/strong><br \/>\n        <\/sup>\n      <\/p>\n<p align=\"left\">\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <sub><br \/>\n          <sup>1<\/sup>\u00a0Note that the other white dots in the lungs are blood vessels.\u00a0<\/sub>\u00a0<\/p>\n<p align=\"justify\">As shown in Figure 1, the lesion in the patient\u2019s right lung (left side of the image) is no longer detectable on the images taken 2 months after treatment with Bria-OTS\u2122 monotherapy.<\/p>\n<p align=\"justify\">This 78-year-old woman with metastatic breast cancer (hormone receptor positive, HER2 negative) had failed several prior lines of therapy and received the lowest dose level in the Phase 1\/2a Bria-OTS\u2122 study. At enrollment on Nov 21, 2024, she had extensive metastases including multiple bone, lymph node and lung metastases.\u00a0Following 4 injections with Bria-OTS\u2122 every 2 weeks, the lung metastasis completely resolved, and she had stable disease elsewhere.<\/p>\n<p align=\"justify\">\u201cDespite recent advancements in cancer treatment with antibody-drug-conjugates (ADCs) and immune check point inhibitors (CPIs), metastatic breast cancer remains an unmet medical need as many patients do not respond to these treatments,\u201d stated Dr. Neal Chawla, Associate Director of Clinical Research at the Sarcoma Oncology Center, and Principal Investigator for the Bria-OTS\u2122 study. \u201cWe are very impressed by the clinical response observed showing rapid and robust clinical activity in addition to excellent tolerability in the first patient treated with Bria-OTS\u2122 and look forward to reproducing these results in other cancer patients in the study.\u201d<\/p>\n<p align=\"justify\">\u201cThis data supports our hypothesis of personalized immunotherapy with Bria-OTS\u2122, potentially leading to new and effective treatment of metastatic breast cancer,\u201d stated Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cWe hope to transform the way we treat cancer patients with our novel personalized off-the-shelf immunotherapy approach.\u201d<\/p>\n<p align=\"justify\">\u201cResolution of metastatic lung disease in this breast cancer patient highlights the clinical effectiveness of Bria-OTS\u2122, and its therapeutic potential in MBC,\u201d commented Dr. Giuseppe Del Priore, BriaCell\u2019s Chief Medical Officer. \u201cThis result represents a major step towards advancing our innovative technology platform and our goal of offering safe and effective treatment to MBC patients and our plans to extend into prostate cancer, melanoma, and lung cancer.\u201d<\/p>\n<p align=\"justify\">The Phase 1\/2a clinical trial is initially evaluating the safety and efficacy of Bria-OTS\u2122 as monotherapy and, later, in combination with an immune checkpoint inhibitor in metastatic breast cancer. Key inclusion criteria include recurrent metastatic breast cancer and at least two failed prior attempts of systemic therapy (e.g., chemotherapy). The study design includes a dose escalation monotherapy phase followed by an expansion phase that will include combination therapy with an immune check point inhibitor.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2eUTXphtri0Fm-9MYpDkXNYASk85gvdaWinwZzgBwgBnN74MpEde_lgKVPnyyyUulKLxMIKKr-DioSBY8ZnwtQk_eQCj6bWJ5BaeLdTvEKs=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release include statements regarding: BriaCell reproducing similar results in other cancer patients in BriaCell\u2019s Phase 1\/2a Bria-OTS\u2122 study; Bria-OTS\u2122 potentially leading to new and effective treatment of metastatic breast cancer; BriaCell transforming the way we treat cancer patients with its novel personalized off-the-shelf immunotherapy approach; the clinical effectiveness of Bria-OTS\u2122 and its therapeutic potential in MBC; BriaCell\u2019s technology offering a safe and effective treatment to MBC patients; BriaCell\u2019s plans to extend into prostate cancer, melanoma, and lung cancer; and BriaCell\u2019s Phase 1\/2a clinical trial initially evaluating the safety and efficacy of Bria-OTS\u2122 as monotherapy and later in combination with an immune checkpoint inhibitor in metastatic breast cancer. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NFctU-NgOqYtXZ54-iiZrk5AfUXQ_2HA78tuLf-7KJR9To-P0P7Q7zkjd7c1Wop3VQbkLumVeylRwEbkwQ7z_BE9KpHsaCvC5grmBy02-FoiWCDiKVYUBc4cAV2YpXMKPCrVvLb8abQ7boJ7WThmQWY6dGjMeXpM5xwPXit2U0s-i_R_6OEb0q0vVCIgPvTY_NkaVCs-uTDdnxM3DVX_QfKgHjqr9raq1JABk6m4vdI=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca<\/strong><\/a><strong>\u00a0<\/strong>and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NFctU-NgOqYtXZ54-iiZrhw1mHWRtJXUXzRfTaKv1c5mEkY8U0kbR2uoqnmWYAPKobu8wYCHhW0IfwGGLKxx_mZ92NifKGMhx-ai31yYbgu4oQ39u2YCjOs-NU_KXzEUyVVtuLBHMS0AR2MNNAwPHRXJJOOJkLhBd1_pxot0nAT3fAFdG6-Bp9hDUT2kfwOilbUY3SF5MQbsSWonQp6IUauK34xkicHAnMZarimy5n0=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HqXjM-QTP7irI-IxD08-uE38oZ7Wt9Ax-Isv7loNIfWTegySzVPxhznXVV0eVAD7KIW8z3wSU5ydNUd2xlZqFxKO5i1ZR7zsUB5b4ICc_zQ=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Jules Abraham<br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gTmhMfOEerg24hRIZbp8QmZO_FTHCyKWro_jSFrvxAplp6xlpSKJlLjncDwT9EsdldyzXc4Br9w0A-2EwbqGqICBJL-6KjIUnuGH3L3jU_M=\" rel=\"nofollow\" target=\"_blank\">julesa@coreir.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3jTOfUFM2GCNoDIbNNOmX3T6CCi0HRZWmU-S3XjNY6HuFlAUqmQ3VYCaq4TXok6dxN746jozhiKqkTyVht-rRnjoYtHVTN0vqmUc8wheZXg=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a><\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2eUTXphtri0Fm-9MYpDkXBAmY4gJ3Bo6xqTT6XB0UjxwnKxedMHlsfAyoHy_3t0xinSXIPDe_eIEwJ35io3s-QF_NKJteddnX3xNcPn-H6sODSEsxjPW_mR-IJxeWRx8nFcnWwlSF7S6dlqY07wQrFJ7D8cFcgLIcSMPUW3yHFguCnD3TihZDQA3Nqn4RgvP3G8Ivo37jXVrt6z4inQ2OpI-b9fe1aVo7i9FMaOmCc_fF6a8OBoWh5V-vb5Vg_5JXQC3UFsfulneSS5Qs_M5xg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/90d9b907-91ef-40c5-ac9f-87ff883327f6<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODQ3MzVlZDktZjY4MS00ZWY3LWI1MGUtZmVhYTQ4ZWEzNDZmLTExMDIyMjk=\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lung metastasis (from metastatic breast cancer) resolved &#8211; after only 2 months (4 doses) of treatment with Bria-OTS\u2122 monotherapy No toxicity related to the treatment; Patient remains on study Unprecedented result in first patient dosed supports Bria-OTS\u2122 personalized immunotherapy approach Ongoing Phase 1\/2a dose escalation study to evaluate Bria-OTS\u2122, BriaCell&#8217;s personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-807698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lung metastasis (from metastatic breast cancer) resolved &#8211; after only 2 months (4 doses) of treatment with Bria-OTS\u2122 monotherapy No toxicity related to the treatment; Patient remains on study Unprecedented result in first patient dosed supports Bria-OTS\u2122 personalized immunotherapy approach Ongoing Phase 1\/2a dose escalation study to evaluate Bria-OTS\u2122, BriaCell&#8217;s personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient &hellip; Continue reading &quot;BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-03T12:34:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122\",\"datePublished\":\"2025-02-03T12:34:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/\"},\"wordCount\":1050,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/\",\"name\":\"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\",\"datePublished\":\"2025-02-03T12:34:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk","og_description":"Lung metastasis (from metastatic breast cancer) resolved &#8211; after only 2 months (4 doses) of treatment with Bria-OTS\u2122 monotherapy No toxicity related to the treatment; Patient remains on study Unprecedented result in first patient dosed supports Bria-OTS\u2122 personalized immunotherapy approach Ongoing Phase 1\/2a dose escalation study to evaluate Bria-OTS\u2122, BriaCell&#8217;s personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce an unprecedented clinical response including resolution of a lung metastasis (breast cancer tumor that spread to the lung) with stable disease elsewhere. This patient &hellip; Continue reading \"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-03T12:34:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122","datePublished":"2025-02-03T12:34:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/"},"wordCount":1050,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/","name":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=","datePublished":"2025-02-03T12:34:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTYwOCM2NzMxNjEwIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/807698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=807698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/807698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=807698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=807698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=807698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}